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Abstract
Purpose: To evaluate the association between commonly measured serum biomarkers of inflammation and penile and testicular cancer 
risk in the Swedish Apolipoprotein-related MORtality RISk (AMORIS) study.
Materials and methods: A total of 205,717 subjects had baseline measurements of C-reactive protein, albumin, and haptoglobin. The 
association between quartiles and dichotomised values of inflammatory markers and penile and testicular cancer risk were analysed by 
using multivariate Cox proportional hazard models. 
Results: A total of 125 men were diagnosed with testicular cancer and 50 with penile cancer during a mean follow-up of 20.3 years. No sta-
tistically significant trends were seen between serum inflammatory markers and risk of penile cancer, but higher albumin levels increased 
the risk of testicular cancer [HR for albumin (g/L): 1.10 (95% CI: 1.03–1.18)]. However, this trend was not observed when using medical 
cut-offs of albumin. 
Conclusions: In the present study, we did not find support for an association between commonly used markers of inflammation and risk of 
testicular or penile cancer. The role of inflammation may be more complicated and require assessment of more specialised measurements 
of inflammation in future studies. 
Keywords: penile cancer, testicular cancer, serum inflammatory markers, albumin, cohort study, survival analysis
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Introduction
About 2300 men are diagnosed with testicular cancer in the United Kingdom each year. More than half of these men are younger 
than 35 years. About 600 men are diagnosed with penile cancer (CRUK) [1]. Even though these cancers are less common, there 
is a need for further research into their potential risk factors as both diseases are associated with a significant reduction of quality 
of life [2]. Second primary tumours, cardiovascular disease, neurotoxicity and ototoxicity, pulmonary complications, hypogonadism, 
and nephrotoxicity are some of the potentially life-threatening long-term complications of testicular cancer and its therapy, whereas 
urethral stenosis, necrosis, reduced voiding ability and sexual function are some of the factors reducing quality of life in men treated 
for penile cancer [3].
Little is known about the risk factors for these rather uncommon cancers. Chronic inflammation is thought to initiate or promote cancer 
through generation of reactive oxygen species and proinflammatory cytokines; and conversely, inflammation may occur secondary to can-
cer and affect disease progression [4]. In this context, many studies have looked into the more common cancers like breast and prostate 
[5]. However, few studies have focused on the role of inflammation in risk of testicular or penila cancer. Studies done on testicular germ cell 
neoplasia have shown that B cells and supporting cytokines, such as IL-6 and CXCL-13, are involved in the immunopathology. The pro-
inflammatory, pro-tumorigenic cytokine environment is likely to facilitate tumour progression and invasion [6]. A Norwegian cohort study of 
586 men with testicular cancer also observed an association between serum levels of C-reactive protein (CRP) and development of second 
primary tumours and cardiovascular disease [7]. In a case–control study with 36 patients with localised testicular cancer, it was found that 
leucocyte counts and neutrophil to lymphocyte ratio were significantly higher in patients with testicular cancer compared with the control 
group [8]. With respect to penile cancer, chronic inflammation caused by persistent human papillomavirus infection has been linked with 
risk of penile cancer as autocrine and paracrine signals are thought to mediate oncogenic action, causing changes in somatic cells under 
the influence of the microbial genome or of epigenetic factors [9]. A German study based on 79 cases found that high pre-operative levels 
of serum CRP were associated with poor survival [10]. In a retrospective study, high pre-surgical CRP levels were significantly associated 
with lymph nodal involvement and poor outcomes [11]. 
Overall, most of studies looking into biomarkers of inflammation and risk of testicular or penile cancer were limited due to small sample 
size and focused on cancer prognosis and quality of life [3], rather than risks of developing these cancers. Hence, the current study aims to 
evaluate the association between serum markers of chronic inflammation and risk of developing testicular or penile cancer. 
Materials and methods
Study population and data collection 
The Swedish Apolipoprotein-related MORtality RISk database (AMORIS) includes blood samples from 812,073 Swedish men and 
women, ranging in age from < 20 to 80 years old and over undergoing occupational health screening or primary care. The cohort is based 
on a linkage between data from laboratory examinations performed in the Central Automation Laboratory (CALAB) in Sweden and infor-
mation recorded in Swedish National Registers using a 10-digit personal identifier number, which is unique to every Swedish resident 
[12]. AMORIS is a large prospective cohort with information on serum biomarkers, cancer diagnosis, comorbidities, vital status, socio-
economic status and emigration. This study complied with the Declaration of Helsinki and was approved by the Ethics Review Board of 
the Karolinska Institute.
We restricted our study population to individuals aged 20 years or older who did not have a previous diagnosis of cancer. Furthermore, 
all subjects were required to have baseline measurements of CRP, albumin, haptoglobin available from the same health examination 
(n = 205,717). The outcome investigated in this study was penile cancer (International Classification of Diseases (ICD), Revision 7 (1955) 
code 179) and testicular cancers (ICD Revision 7 (1955) code 178) [13].
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Serum CRP (mg/L), albumin (g/L), haptoglobin (g/L), triglycerides (mmol/L), total cholesterol (mmol/L), glucose (mmol/L), uric acid and 
creatinine were measured at baseline with standard laboratory methods as described elsewhere [14]. High-sensitive CRP (hsCRP) was not 
available at any time in the period of blood sample collection (1985–1996), so that CRP concentrations < 10 mg/L could not be measured 
precisely [15]. However, the cut-off point of 10 mg/L is widely accepted as the upper limit of the health-associated reference range and was 
therefore used in this study [16]. Levels of serum inflammatory markers were assessed as high or low based on their clinical cut-offs used 
in CALAB: CRP 10 mg/L and haptoglobin 1.4 g/L. For albumin, a cut-off point of 40 g/L was used instead of 35 g/L due to the small number 
of participants with low albumin levels. 
Serum glucose, total cholesterol, and triglycerides levels were dichotomised using clinical cut-offs in accordance with the American Diabe-
tes Association and National Cholesterol Education Programme (NCEP) guidelines (cut-offs: 6.11, 6.50 and 1.71 mmol/L for glucose, total 
cholesterol and triglycerides, respectively) [17]. In addition, the following baseline information was obtained from AMORIS: educational 
level (low, intermediate, high), Charlson comorbidity Index (CCI; 0, 1, 2, ≥ 3) and fasting status (fasting, non-fasting, missing). Follow-up 
time was defined as the time from baseline measurements until date of cancer diagnosis, date of death, emigration or end of study (31st 
December 2011), whichever came first. 
Data analyses
We estimated the risk of penile and testicular cancer with multivariate Cox proportional hazards regression, comparing people with high to 
low levels of CRP, albumin and haptoglobin, respectively. Cox regression models were adjusted for age, sex, education and CCI, as well 
as triglycerides (continuous), glucose (continuous), total cholesterol (continuous), fasting status, uric acid (continuous) and creatinine (con-
tinuous). The assumption of proportional hazards was evaluated by adding time-dependent covariates into the models and assessment of 
the Schoenfeld Residuals.
Based on current evidence, the World Trade Center Program Administrator under Centers for Disease Control and Prevention (CDC) 
sets the minimum latency for thyroid cancer as 2.5 years, which is well covered within our follow-up time [18]. Nevertheless, we assessed 
reverse causality through two sensitivity analyses excluding those with follow-up time < 3 years and < 5 years, respectively. 
For those biomarkers where we observed an association based on the hazard ratios, we used the restrictive cubic spline (RCS) function to 
graphically display the hazard ratios representing the dose–response association. We used knots located at the 5th, 25th, 75th, and 95th 
percentiles as well as the medical reference value [19] in a multivariate Cox proportional hazards model as described above. This analysis 
was performed using the RCS_Reg SAS Macro created by Desquilbet and Mariotti [20]. All analyses were conducted with Statistical Analy-
sis Systems (SAS) software release 9.4 (SAS Institute, Cary, NC) [21].
Results
Characteristics of study participants are shown in Table 1. A total of 125 men developed testicular cancer and 50 men developed penile 
cancer during a mean follow-up of 8.9 years and 13.3 years, respectively (20.3 years in the cohort who did not develop penile or testicular 
cancer). No statistically significant trends were seen between the included serum inflammatory markers and risk of penile cancer, but higher 
albumin levels were associated with an increased risk of testicular cancer [HR for albumin (g/L): 1.10 (95% CI: 1.03–1.18)]. However, this 
trend was not observed when using medical cut-offs of albumin (Table 2). 
To further evaluate the potential association between serum albumin and risk of testicular cancer, we modelled a dose–response curve 
with restrictive cubic splines (Figure 1). The shape of the curve was consistent with the direction of the hazard ratios observed. A sensitiv-
ity analysis to assess reverse causation by excluding those with follow-up time < 3 years and < 5 years did not affect the above findings 
(results not shown). 
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Table 1. Descriptive statistics of the study population by cancer status
All men (n = 205,717)
Penile cancer 
(n = 50)
Testicular  
cancer (n = 125)
No cancer 
(n = 205,542)
Mean age (yrs.) (SD) 51.0 (10.6) 35.3 (10.3) 43.8 (11.5)
Socio-economic status (%)
White collar 32 (64.00) 65 (52.00) 103,405 (50.31)
Blue collar 17 (34.00) 50 (40.00) 93,075 (45.28)
Unemployed/missing 1 (2.00) 10 (8.00) 9062 (4.41)
Education (%)
Low 19 (38.00) 24 (19.20) 52,449 (25.52)
Middle 20 (40.00) 60 (48.00) 91,095 (44.32)
High 11 (22.00) 41 (32.80) 57,891 (28.16)
Missing 0 (0.00) 0 (0.00) 4107 (1.99)
Charslon Comorbidity Index (%)
0 45 (90.00) 120 (96.00) 193,191 (93.99)
1 4 (8.00) 3 (2.40) 6926 (3.37)
2 1 (2.00) 2 (1.60) 4148 (2.02)
3+ 0 (0.00) 0 (0.00) 1277 (0.62)
Body mass index (kg/m2) (%)
 < 18.5 0 (0.00) 0 (0.00) 773 (0.37)
18.5–24.99 8 (16.00) 20 (16.00) 26,570 (12.93)
25–29.99 5 (10.00) 8 (6.40) 14,298 (6.96)
 ≥ 30 3 (6.00) 1 (0.80) 3483 (1.69)
Missing 34 (68.00) 96 (76.80) 160,418 (78.05)
CRP (mg/L) (%)
Mean (SD) 3.90 (1.0) 7.69 (1.0) 5.41 (3.0)
 < 10 44 (88.00) 102 (81.60) 170,859 (83.13)
 ≥ 10 6 (12.00) 23 (18.40) 34,683 (16.87)
Albumin (g/L) (%)
Mean (SD) 42.42 (43.0) 44.41 (44.0) 42.92 (43.0)
 < 40 7 (14.00) 3 (2.40) 20,838 (10.14)
 ≥ 40 43 (86.00) 122 (97.60) 184,704 (89.86)
Haptoglobin (g/L) (%)
Mean (SD) 1.11 (1.10) 0.98 (1.0) 1.04 (1.0)
 < 1.4 44 (88.00) 112 (89.60) 178,771 (86.97)
 ≥ 1.4 6 (12.00) 13 (10.40) 26,771 (13.02)
Fasting status (%)
Fasting 32 (64.00) 69 (55.20) 127,396 (61.98)
Not fasting 18 (36.00) 56 (44.80) 76,540 (37.24)
Missing 0 (0.00) 0 (0.00) 1606 (0.78)
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Table 1. Continued.
Fasting glucose (mmol/L) (%)
Mean (SD) 5.10 (0.75) 4.86 (0.84) 4.90 (1.21)
 < 6.11 46 (92.00) 116 (92.80) 193,211 (94.0)
 ≥ 6.11 4 (8.00) 9 (7.20) 10,725 (5.22)
Missing 0 (0.00) 0 (0.00) 1606 (0.78)
Triglycerides (mmol/L) (%)
Mean (SD) 1.76 (0.96) 1.21 (0.79) 1.31 (1.06)
 < 1.71 27 (55.10) 103 (82.40) 162,839 (79.22)
>=1.71 22 (44.90) 22 (17.60) 41,189 (20.04)
Missing 1 (0.02) 0 (0.00) 1514 (0.74)
Total cholesterol (mmol/L) (%)
Mean (SD) 5.75 (0.96) 5.15 (1.09) 5.54 (1.12)
 < 6.5 38 (76.00) 113 (90.40) 164,141 (79.86)
 ≥ 6.5 12 (24.00) 12 (9.60) 39,894 (19.41)
Missing 0 (0.00) 0 (0.00) 1507 (0.73)
Uric acid (%)
Mean (SD) 325.68 (55.19) 305.68 (55.16) 284.61 (71.12)
Missing 0 (0.0) 1 (0.8) 1967 (0.96)
Creatinine (%)
Mean (SD) 89.36 (11.75) 86.18 (10.27) 80.26 (14.16)
Missing 0 (0.0) 1 (0.8) 1458 (0.71)
Table 2. Hazard ratio (HR) for risk of testicular and penile cancer, with 95% confidence intervals (CI) from Cox proportional hazards model. 
Penile cancer (n = 50) Testicular cancer (n = 125)
Crude Adjusted1 Adjusted2 Crude Adjusted1 Adjusted2
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
CRP (mg/L)
Continuous 0.97 (0.91–1.03) 0.96 (0.9–1.03) 0.95 (0.89–1.02) 1.00 (0.99–1.01) 1.00 (0.99–1.01) 1.00 (0.99–1.01)
 ≥ 10 0.59 (0.25–1.41) 0.55 (0.23–1.30) 0.52 (0.22–1.24) 1.07 (0.68–1.68) 1.13 (0.71–1.78) 1.03 (0.65–1.65)
Albumin (g/L)
Continuous 0.93 (0.84–1.03) 1.76 (0.50–6.16) 0.98 (0.88–1.10) 1.21 (1.14–1.29) 1.13 (1.06–1.21) 1.10 (1.03–1.18)
 ≤ 40 1.52 (0.68–3.37) 1.14 (0.51–2.56) 1.20 (0.53–2.72) 0.22 (0.07–0.71) 0.29 (0.09–0.93) 0.35 (0.11–1.09)
Haptoglobin (g/L)
Continuous 1.99 (0.91–4.34) 1.43 (0.62–3.31) 1.20 (0.51–2.84) 0.49 (0.26–0.96) 0.79 (0.41–1.54) 0.68 (0.35–1.32)
 ≥ 1.4 0.97 (0.41–2.28) 0.78 (0.33–1.84) 0.68 (0.29–1.61) 0.81 (0.46–1.44) 1.07 (0.59–1.91) 0.89 (0.49–1.64)
1adjusted for age, sex, education, Charslon Comorbidity Index.
2adjusted for age, sex, education, Charslon Comorbidity Index, triglyceride (continuous), glucose (continuous), total cholesterol (continuous), fasting  
 status, urea (continuous), creatinine (continuous).
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Figure 1. Dose response relationship between serum albumin levels and HR of testicular cancer by RCS curve with 5 knots of albumin values at 
5th, 25th, 50th, 75th, 95th percentiles [Reference value of albumin = 40 g/L]
Discussion
In the present study, we found that higher serum albumin levels are associated with higher risks of testicular cancer in the AMORIS cohort, 
but no association was observed between serum levels of CRP or haptoglobin and risks of penile or testicular cancer. 
Most of the studies on testicular cancer have focussed on tumour immunity and have shown that B cells and B-cell-supporting cytokines, 
such as IL-6 and CXCL-13, are involved in the immunopathology of testicular germ cell neoplasia. In those studies, it has been emphasised 
that the pro-inflammatory, pro-tumorigenic cytokine environment likely facilitates tumour progression and invasion [6]. In the case of penile 
cancer, studies have mostly focussed on viral aetiology of carcinogenesis like in the case of human papillomavirus (HPV)–induced penile 
cancers. They have stressed on the associations between chronic inflammation, persistent infection, and cancer, where autocrine and 
paracrine signals mediate oncogenic action, causing changes in somatic cells under the influence of the microbial genome or of epigenetic 
factors [9]. None of the studies have considered systemic markers of inflammation and carcinogenesis. Most of the studies investigating 
serological biomarkers in context of penile [10, 11] and testicular cancers [8, 22–24] have investigated on disease diagnosis, progression, 
treatment response, and late side effects with little focus on risks.
In our study, analysis of CRP and haptoglobin in relation to risks of these cancers have showed no association, but serum levels of 
albumin were found to be positively related to the risk of subsequent development of testicular cancer. The observed association slightly 
weakened when the model was adjusted for potential confounders. These findings suggest the importance of commonly measured bio-
marker like albumin to predict the risks of testicular cancer patients. However, detailed explanation for the observed association could not 
be generated, as it was outside the scope of this project and needs further basic research. To date, this is the largest prospective study 
assessing common serum inflammatory markers in relation to these cancers. Nevertheless, there were some limitations that need careful 
acknowledgement. 
The strength of studies conducted within AMORIS lies in the prospective evaluation of exposures and complete follow-up of study partici-
pants. All analyses were performed at the same laboratory with internationally accredited and calibrated methods [14]. The population in 
AMORIS was selected by analysing fresh blood samples from health check-ups in non-hospitalised persons; however, possibility of batch 
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effects, human error in data imputation, and missing data cannot be ruled out [25]. Any healthy worker effect would not influence the inter-
nal validity of the conducted studies. Information on race/ethnicity was not available, but the AMORIS cohort was like the general working 
population of Stockholm [26], which comprised about 90% in 1990 and 80% Swedish-born individuals in the year 2000 [27]. 
It is a limitation that we did not have high-sensitive CRP available at the time measurements were conducted. Any CRP levels < 10 mg/L 
were unquantifiable, which may have resulted in an underestimation of the association between serum CRP and these cancers. Informa-
tion on BMI was only available for a small proportion of the participants in the current subset of AMORIS participants. There was limited 
information for other potential confounders such as smoking habits, history of HPV infection, tumour histology or other serum inflamma-
tory markers such as IL-6 or IL-8. However, all models were adjusted for Charlson Comorbidity Index. The different histological variants of 
penile or testicular cancers might have different courses in their natural history of carcinogenesis [28, 29], but that could not be verified in 
the present study.
Conclusion
In the present study, we did not find support for an association between commonly used markers of inflammation and risk of testicular or 
penile cancer. Future studies should investigate temporality of associations between inflammation and these cancers using a modelling 
approach based on repeated measurement of time-to-event data with more detailed markers of systemic inflammation to provide more 
insight into these possible links. 
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